No Data
Hitgen Inc. (688222.SH): "The first subject has been enrolled in the Phase II clinical trial of the HG146 capsule."
On December 27, according to Gelonghui, Hitgen Inc. (688222.SH) announced that its independently developed class 1 anti-tumor Innovative Drug "HG146 capsule" (referred to as "HG146") (Pharmaceutical code: HG146) for the treatment of recurrent or metastatic adenoid cystic carcinoma has completed the enrollment of the first subject in the Phase II clinical trial "HG146CN201." HG146 (HDACI/IIb subtype selective small molecule inhibitor) is a selective inhibitor of class I and IIb histone deacetylases (HDAC) developed by Hitgen Inc., which began in April 2018 and April 2021.
HitGen (SHSE:688222) Has A Rock Solid Balance Sheet
Hitgen Inc. (688222.SH): Jun Tian Venture Capital and Bo Yi Xin Tian plan to collectively reduce their shareholding by no more than 2.01%.
On November 19, Gelunhui reported that Hitgen Inc. (688222.SH) disclosed that Juntian Venture Capital intends to reduce its holdings of the company's shares by no more than 1,831,448 shares through block trading or bulk trading, with the proportion of the shares to be reduced accounting for approximately 0.46% of the company's total share capital. Boyi New World intends to reduce its holdings of the company's shares by no more than a total of 6,217,637 shares through block trading or bulk trading, with the proportion of the shares to be reduced accounting for approximately 1.55% of the company's total share capital.
HitGen Inc. (SHSE:688222) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Chengdu Pilot Drug Development Co., Ltd. Report for the Third Quarter of 2024
hitgen inc. (688222.SH) announced its performance for the first three quarters, with a net income of 30.12 million yuan, a year-on-year increase of 64.71%.
hitgen inc. (688222.SH) disclosed the third quarter report of 2024, achieving revenue of 2....
Time To Worry? Analysts Are Downgrading Their HitGen Inc. (SHSE:688222) Outlook
